Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 551-560

  Gallamini, Andrea ^a   Patti, Caterina ^b   Viviani, Simonetta ^c   Rossi, Andrea ^d   Fiore, Francesca ^a   Di Raimondo, Francesco ^e   Cantonetti, Maria ^f   Stelitano, Caterina ^g   Feldman, Tatyana ^h   Gavarotti, Paolo ⁱ   Sorasio, Roberto ^a   Mulè, Antonino ^b   Leone, Monica ^b   Rambaldi, Alessandro ^d   Biggi, Alberto ^a   Barrington, Sally ^j   Fallanca, Federico ^k   Ficola, Umberto ^l   Chauvie, Stéphane ^a   Gianni, Alessandro Massimo ^c  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g Bianchi and Melacrino Hospital ^*  (Italy)

^h Hackensack University Medical Center   (United States)

ⁱ MOLINETTE HOSPITAL   (Italy)

^j KING'S COLLEGE LONDON   (United Kingdom)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l LA MADDALENA CANCER CENTER   (Italy)

more..

Author keywords

ABVD; BEACOPP; Hodgkin lymphoma; Positron emission tomography; Review panel

Indexed keywords

BLEOMYCIN SULFATE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IFOSFAMIDE; MELPHALAN; NAVELBINE; PREDNISONE; PROCARBAZINE; VINBLASTINE SULFATE; VINCRISTINE SULFATE;

ADULT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DYSPNEA; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; DRUG SUBSTITUTION; EPIDEMIOLOGIC METHODS; ETOPOSIDE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDNISONE; PROCARBAZINE; PROGNOSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 79951524764     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08485.x     Document Type: Article

References (48)

1. Avigdor, A., Bulvik, S., Levi, I., Dann, E.J., Shemtov, N., Perez-Avraham, G., Shimoni, A., Nagler, A., Ben-Bassat, I. & Polliack, A. (2010) Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma. Annals of Oncology, 21, 126-132.
2. Barrington, S.F., Qian, W., Somer, E.J., Franceschetto, A., Bagni, B., Brun, E., Almquist, H., Loft, A., Højgaard, L., Federico, M., Gallamini, A., Smith, P., Johnson, P., Radford, J. & O'Doherty, M.J. (2010) Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 37(10): 1824-33. Epub 2010 May 27.
3. Behringer, K., Breuer, K., Reineke, T., May, M., Nogova, L., Klimm, B., Schmitz, T., Wildt, L., Diehl, V., Engert, A.; German Hodgkin's Lymphoma Study Group (2005) Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Journal of clinical Oncology, 23, 7555-7564.
4. Bombardieri, E., Aktolun, C., Baum, R.P., Bishof-Delaloye, A., Buscombe, J., Chatal, J.F., Maffioli, L., Moncayo, R., Mortelmans, L. & Reske, S.N. (2003) FDG-PET: procedure guidelines for tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging, 30, BP115-BP124.
5. Bonadonna, G., Viviani, S., Bonfante, V., Gianni, A.M. & Valagussa, P. (2005) Survival in Hodgkin's disease patients - Report of 25years of experience at the Milan cancer Institute. European Journal of Cancer, 41, 998-1006.
6. Canellos, G.P. & Niedzwiecki, D. (2002) Long term follow-up of Hodgkin's disease trial. New England Journal of Medicine, 346, 1417-1418.
7. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. New England Journal of Medicine, 327, 1478-1484.
8. Chauvie, S., Stancu, A., Cerello, P., Biggi, A. & Gallamini, A. (2009) A clinical trial toolkit for diagnostic imaging exchange through the WEB [abstract]. Proceedings of 22nd Annual EANM Meeting; 2009 October 10; Barcelona, Spain: abstract P-234.
9. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M., Diehl, V.; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
10. ClinicalTrials.gov [Internet]. University of Cologne. HD18 for Advanced Stages in Hodgkin's Lymphoma; 2007. Available from: Accessed 8 March 2010.
11. ClinicalTrials.gov [Internet]. Gruppo Italiano Terapie Innovative nei Linfomi (GITIL). Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL); 2008a. Available from: Accessed 27 October 2009.
12. ClinicalTrials.gov [Internet]. National Cancer Institute (NCI). Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma; 2008b. Available from: Accessed 26 June 2009.
13. ClinicalTrials.gov [Internet]. Fondazione Intergruppo Italiano Linfomi Onlus (IIL). High-Dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD (HD0802) and Comparison of RT Versus no RT in PET-2 Negative Patients (HD0801); 2008c. Available from: Accessed 18 December 2008.
14. ClinicalTrials.gov [Internet]. National Cancer Institute (NCI). Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma; 2009. Available from: Accessed 24 April 2010.
15. Cohen, J. (1960) A coefficient for agreement for nominal scales. Educational and Psychological Measurement, 20, 37-46.
16. Cox, D.R. (1972) Regression models and life tables. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 34, 187-220.
17. Dann, E.J., Bar-Shalom, R., Tamir, A., Haim, N., Ben-Shachar, M., Avivi, I., Zuckerman, T., Kirschbaum, M., Goor, O., Libster, D., Rowe, J.M. & Epelbaum, R. (2007) Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood, 109, 905-909.
18. Delbeke, D., Coleman, R.E., Guiberteau, M.J., Brown, M.L., Royal, H.D., Siegel, B.A., Townsend, D.W., Berland, L.L., Parker, J.A., Hubner, K., Stabin, M.G., Zubal, G., Kachelriess, M., Cronin, V. & Holbrook, S. (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. Journal of nuclear Medicine, 47, 885-895.
19. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.K., Dühmke, E., Loeffler, M.; German Hodgkin's Lymphoma Study Group (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
20. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.K., Hasenclever, D. & Löffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4555.
21. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M., Gobbi, P.G.; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's Lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of clinical Oncology, 27, 805-811.
22. Freedman, A.S., Neuberg, D., Mauch, P., Soiffer, R.J., Anderson, K.C., Fisher, D.C., Schlossman, R., Alyea, E.P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L.M. & Gribben, J.G. (1999) Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood, 94, 3325-3333.
23. Gallamini, A., Raviolo, E., Merli, F., Rigacci, L., Nassi, L. & Santini, S. (2004) Predictive value of positron emission tomography (PET) performed after two cycles of standard chemotherapy on treatment outcome in Hodgkin disease [abstract]. European Journal of Haematology, 73(Suppl 65), abstract D04.
24. Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A., Capodanno, I., Luminari, S., Vitolo, U., Sancetta, R., Iannitto, E., Trentin, L., Stelitano, C., Tavera, S., Biggi, A., Castagnoli, A., Versari, A., Gregianin, M., Pelosi, E., Torchio, P. & Levis, A. (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 91, 475-481.
25. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
26. Gianni, A.M., Rambaldi, A., Zinzani, P.L., Levis, A., Brusamolino, E. & Pulsoni, A. (2008) Comparable 3-year outcome following ABVD or BEACOPP first-line chemotherapy, plus pre-planned high-dose salvage, in advanced Hodgkin lymphoma (HL): a randomized trial of the GITIL and IIL cooperative groups [abstract]. Journal of Clinical Oncology, 26(Suppl 20), abstr 8506.
27. Gobbi, P.G., Pieresca, C., Federico, M., Di Renzo, N., Narni, F., Iannitto, E., Grignani, G., Cavanna, L., Avanzini, P. & Partesotti, G. (1993) MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: a report from the Italian Lymphoma Study Group. Journal of Clinical Oncology, 11, 712-719.
28. Gobbi, P.G., Zinzani, P.L., Broglia, C., Comelli, M., Magagnoli, M., Federico, M., Merli, F., Iannitto, E., Tura, S. & Ascari, E. (2001) Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer, 91, 1467-1478.
29. Hasenclever, D. (2002) The disappearance of prognostic factors in Hodgkin's disease. Annals of Oncology, 13(Suppl 1), 75-78.
30. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
31. Hutchings, M. & Barrington, S.F. (2009) PET/CT for therapy response assessment in Lymphoma. Journal of Nuclear Medicine, 50(Suppl 1), 21S-30S.
32. Hutchings, M., Mikhaeel, N.G., Fields, P.A., Nunan, T. & Timothy, A.R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals of Oncology, 16, 1160-1168.
33. Hutchings, M., Eigtved, A. & Specht, L. (2004) Early prediction of chemotherapy treatment response in Hodgkin lymphoma with positron emission tomography [abstract]. European Journal of Haematology, 73(Suppl 65), abstract D05.
34. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.M., Berthelsen, A.K. & Specht, L. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52-59.
35. Josting, A., Wiedenmann, S., Franklin, J., May, M., Sieber, M., Wolf, J., Engert, A., Diehl, V.; German Hodgkin's Lymphoma Study Group. (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology, 21, 3440-3446.
36. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
37. Kostakoglu, L., Coleman, M., Leonard, J.P., Kuji, I., Zoe, H. & Goldsmith, S.J. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. Journal of Nuclear Medicine, 43, 1018-1027.
38. Kostakoglu, L., Goldsmith, S.J., Leonard, J.P., Christos, P., Furman, R.R., Atasever, T., Chandramouly, A., Verma, S., Kothari, P. & Coleman, M. (2006) FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer, 107, 2678-2687.
39. Landau, S. & Everitt, B.S. (2004) A Handbook of Statistical Analyses Using SPSS. Chapman & Hall/CRC, Boca Raton, FL.
40. Landis, J.R. & Koch, G.G. (1977) The measurement of observer agreement for categorical data. Biometrics, 33, 159-174.
41. Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Rosenberg, S.A., Coltman, C.A. & Tubiana, M. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. Journal of Clinical Oncology, 7, 1630-1636.
42. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
43. Meignan, M., Gallamini, A. & Haioun, C. (2009) Report on the first international workshop on interim-PET scan in Lymphoma. Leukemia and Lymphoma, 50, 1257-1260.
44. Rambaldi, A., Carlotti, E., Oldani, E., Della Starza, I., Baccarani, M., Cortelazzo, S., Lauria, F., Arcaini, L., Morra, E., Pulsoni, A., Rigacci, L., Rupolo, M., Zaja, F., Zinzani, P.L., Barbui, T. & Foa, R. (2005) Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts lymphoma treatment response and long-term outcome in follicular non-Hodgkin lymphoma. Blood, 105, 3428-3433.
45. Rigacci, L., Castagnoli, A., Carpaneto, A., Carrai, V., Vaggelli, L. & Matteini, M. (2002) Can (18)F-FDG PET after first cycle chemotherapy predict the efficacy of therapy in Hodgkin's disease? Haematologica, 87, ELT24.
46. Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T. & Nagai, H. (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. Journal of Clinical Oncology, 27, 1906-1914.
47. Ziakas, P.D. & Poulou, L.S. (2008) Improving outcome after positive interim PET in advanced Hodkin's disease: reality vs. expectation. European Journal of Nuclear Medicine and Molecular Imaging, 35, 1573-1575.
48. Zinzani, P.L., Tani, M., Fanti, S., Alinari, L., Musuraca, G., Marchi, E., Stefoni, V., Castellucci, P., Fina, M., Farshad, M., Pileri, S. & Baccarani, M. (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Annals of Oncology, 17, 1296-1300.